Latest News
7/7/10 - Novel Phase I clinical investigations reduce costs and increase efficiency
Date Posted: |
07 Jul 2010 |
Summary: |
Mike Butler, Xceleron CEO, discusses ways to overcome early clinical development hurdles. |
Download: |
 Xceleron_NGP EU Final June2010.pdf Download |
|
In NGP EU Q3 edition, Mike Butler discusses some of the ways Xceleron is helping to reduce late stage failure by offering innovative Phase I services by which human metabolism and absolute bioavailability can be elucidated. Mike also discusses areas where Phase 0/Human Microdosing has been most useful.
Click to see more news
